Is Exenatide a Treatment for Parkinson’s Disease?-Reference-Cited by-同舟云学术

Is Exenatide a Treatment for Parkinson’s Disease?

Published:2017-08-08 Issue:3 Volume:7 Page:451-458
ISSN:1877-7171
Container-title:Journal of Parkinson's Disease
language:
Short-container-title:JPD

Author:

Athauda Dilan¹,Wyse Richard²,Brundin Patrik³,Foltynie Thomas¹

Affiliation:

1. Sobell Department of Motor Neuroscience, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

2. Cure Parkinson’s Trust, London, UK

3. Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, Michigan, USA

Publisher

IOS Press

Subject

Cellular and Molecular Neuroscience,Clinical Neurology

Reference16 articles.

1. Central effects of GLP-1: New opportunitiesfor treatments of neurodegenerative diseases;Hölscher;JEndocrinol,2014

2. Exenatide and the treatment of patients with Parkinson’s disease;Aviles-Olmos;J Clin Invest,2013

3. Motor and cognitive advantages persist 12 months after Exenatide exposure in Parkinson’s disease;Aviles-Olmos;J Parkinsons Dis,2014

4. Athauda D , Maclagan K , Skene SS , Bajwa-joseph M , Letchford D , Chowdhury K , Hibbert S , Budnik N , Zampedri L , Dickson J , Li Y , Aviles-olmos I , Warner TT , Limousin P , Lees AJ , Greig NH , & Tebbs S (2017) A randomised, double-blind, placebo controlled trial of Exenatide once-weekly in Parkinson’s disease. Lancet, in press.

5. Disease-modifying strategiesfor Parkinson’s disease;Kalia;Mov Disord,2015

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C-phycocyanin shows neuroprotective effect against rotenone-induced Parkinson’s disease in mice;Asian Pacific Journal of Tropical Biomedicine;2024-07

2. Protein misfolding and related human diseases: A comprehensive review of toxicity, proteins involved, and current therapeutic strategies;International Journal of Biological Macromolecules;2022-12

3. Deciphering Intertwined Molecular Pathways Underlying Metabolic Syndrome Leading to Parkinson’s Disease;ACS Chemical Neuroscience;2022-07-20

4. Cardiovascular Risk Factors and Phenoconversion to Neurodegenerative Synucleinopathies in Idiopathic REM Sleep Behavior Disorder;Journal of Parkinson's Disease;2022-04-05

5. The Role of Clinical Medicine;Drug Repurposing;2022-02-09